(Q33334770)

English

High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacy (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

G H Jackson

1

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

B Angus

2

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

P J Carey

3

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

R D Finney

4

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

M J Galloway

5

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

D K Goff

6

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

A Haynes

7

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

A L Lennard

8

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

R C Leonard

9

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

I G McQuaker

10

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

S J Proctor

11

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

N Russell

12

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

K Windebank

13

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

P R Taylor

14

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Scotland and Newcastle Lymphoma Group

15

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

publication date

1 May 2000

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

37

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

5-6

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

561-570

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Hodgkin's disease: a population-adjusted clinical epidemiology study (PACE) of management at presentation. Northern Region Lymphoma Group

1 reference

https://api.crossref.org/works/10.3109%2F10428190009058508

21 January 2018

Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group

1 reference

https://api.crossref.org/works/10.3109%2F10428190009058508

21 January 2018

A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428190009058508

21 January 2018

Twin-track studies of ifosfamide and mitoxantrone (I-M) in recurrent high grade non-Hodgkin's lymphoma and Hodgkin's disease. Yorkshire Regional Lymphoma and Central Lymphoma Groups.

1 reference

https://api.crossref.org/works/10.3109%2F10428190009058508

21 January 2018

Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD)

1 reference

https://api.crossref.org/works/10.3109%2F10428190009058508

21 January 2018

An effective oral combination in advanced relapsed Hodgkin's disease prednisolone, etoposide, chlorambucil and CCNU.

1 reference

https://api.crossref.org/works/10.3109%2F10428190009058508

21 January 2018

Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.

1 reference

https://api.crossref.org/works/10.3109%2F10428190009058508

21 January 2018

Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.3109%2F10428190009058508

21 January 2018

Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.3109%2F10428190009058508

21 January 2018

Prediction of ifosfamide/mesna associated encephalopathy

1 reference

https://api.crossref.org/works/10.3109%2F10428190009058508

21 January 2018

Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.3109%2F10428190009058508

21 January 2018

Identifiers

10.3109/10428190009058508

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33334770&oldid=1951794763"